액섬 테라퓨틱스 (AXSM) 주가 전망: 목표주가, 배당, 최신 뉴스

Axsome Therapeutics, Inc. , a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.

It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder.

It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.는 미국에서 중추신경계(CNS) 질환 관리를 위한 신규 치료제를 개발·공급하는 바이오제약 회사입니다.

상업용 제품 포트폴리오에는 성인 주요우울장애 치료에 허가된 Auvelity(데스트로메토르판-부프로피온; NMDA 수용체 길항제·시그마-1 수용체 작용제·아미노케톤 계열·CYP2D6 억제제), 기면증 또는 폐쇄성 수면무호흡 환자의 과도한 주간 졸림증 개선에 적응증이 있는 Sunosi(솔리아엠페톨; 도파민·노르에피네프린 재흡수 억제제, 트레이스아민 관련 수용체1 작용제, 5-HT1A 작용제), 그리고 편두통 급성 치료에 적응증을 가진 빠르게 흡수되는 다중 기전 약물인 Symbravo(MoSEIC meloxicam rizatriptan, AXS-07; 선택적 COX-2 억제제·5-HT1B/1D 작용제) 등이 포함됩니다.

임상 파이프라인으로는 AXS-05(데스트로메토르판-부프로피온)가 알츠하이머병 관련 초조 행동 치료를 위한 Phase III를 완료했으며 금연 치료를 위한 Phase II를 완료했고, AXS-12(레복세틴)는 기면증 치료를 위한 Phase II를 완료했습니다. AXS-14(에스레복세틴)는 섬유근통 등 치료를 위한 Phase III를 완료했으며, Solriamfetol은 주의력결핍 과다행동장애(ADHD), 주요우울장애, 폭식장애, 교대근무 관련 과다졸림증 등을 적응증으로 Phase III 진행 중입니다. 또한 AXS-05의 금연 치료 평가를 위해 Duke University와 연구 협력 계약을 체결해 임상 연구를 진행하고 있습니다. 회사는 2012년에 설립되어 뉴욕에 본사를 두고 있습니다.

• 주소: One World Trade Center, 29th Floor, New York, NY 10007, United States

• 전화번호: 212 332 3241

• 웹사이트: https://www.axsome.com

• 섹터: Healthcare

• 산업: Biotechnology

• 직원 수: 1,220